Policy

March 19, 2019

A new law that allows patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits went into effect yesterday. The bill, known as the “Improving Access to Clinical Trials Act” (IACT), was signed into law in October 2010. Because of...

FDA Panel Not Sold on Personal Genetic Testing

by BEF

CF News, Policy

March 19, 2019

A Food and Drug Administration advisory panel said March 8 that genetic tests directly marketed to consumers should be allowed only under a doctor's supervision. Personal testing, which is mainly available online from firms operating outside traditional medical institutions, can produce ambiguous or misleading results without...

‘Improving Access to Clinical Trials Act’ Passes U.S. House; Heads to President for Signatur

by BEF

CF News, Policy

March 19, 2019

The U.S. House of Representatives passed the "Improving Access to Clinical Trials Act" (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations. The bill, which passed the Senate Aug. 5, now goes to President Obama's desk for his...

‘Improving Access to Clinical Trials Act’ Passes U.S. Senate in Victory for CF Advocates

by BEF

CF News, Policy

March 19, 2019

The U.S. Senate last night passed the "Improving Access to Clinical Trials Act" (I-ACT), a bipartisan piece of legislation championed by the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations. The legislation enables patients with rare diseases to participate in clinical trials without...

Policy

Clinical Trials Legislation Takes Effect

FDA Panel Not Sold on Personal Genetic Testing

‘Improving Access to Clinical Trials Act’ Passes U.S. House; Heads to President for Signatur

‘Improving Access to Clinical Trials Act’ Passes U.S. Senate in Victory for CF Advocates

Never miss an update. Subscribe to our emails!